The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis.
acne inversa
dermatology
hidradenitis suppurativa
pain
pruritus
quality of life
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
received:
21
05
2021
revised:
19
06
2021
accepted:
21
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
8
2021
Statut:
epublish
Résumé
Hidradenitis suppurativa (HS) is a chronic, recurrent and debilitating inflammatory skin disease of the hair follicle that usually presents as painful, deep-seated inflamed lesions in the apocrine gland-bearing areas of the body. HS patients suffer from uncomfortable signs and symptoms, such as pain, pruritus, malodour and suppuration, which may impair patients' quality of life (QoL). Although HS patients frequently experience these signs and symptoms, they are only occasionally assessed by clinicians and, unexpectedly, the scientific evidence available is limited and heterogeneous. The aim of this study is to summarize the evidence regarding the impact of HS signs and symptoms on QoL to serve as a basis for future research and help clinicians to consider them in the daily care of HS patients. A systematic review and meta-analysis were conducted following PRISMA Guidelines. The following search algorithm was used: (hidradenitis or "acne inversa") and (pain or itch or odour or malodour or suppuration or oozing or drainage) and ("quality of life"). The literature search identified 836 references, 17 of them met the eligible criteria and were included for analysis, representing 4929 HS patients. Mean age of the participants was 36.28 years and there was a predominance of female sex among study participants. The BMI of the population was in the range of over-weight and about two out five patients were active smokers. Studies included patients with mild to moderate HS, with a mean disease duration of 13.69 years. The HS signs and symptoms assessed were pain, pruritus, malodour and suppuration. Overall, the higher intensity of a sign or symptom correlated with poorer general QoL or specific QoL dimensions including sexual distress, anxiety, depression and sleep. The most frequently employed tool to assess QoL was the Dermatology Life Quality Index (DLQI). DLQI was used in 52.9% of the studies (9/17) with a mean value of 10.70 (2.16 SD). The scores employed to assess signs and symptoms severity were subjective and varied between studies, being the numerical rating scale (NRS) for each of the most used symptoms. The mean NRS value for pain was 3.99 and the mean NRS for pruritus was 4.99. In conclusion, we have summarized, categorized and analyzed the scientific evidence regarding signs and symptoms in HS patients and their impairment in QoL. Their assessment should be thorough and included during routine evaluation of HS patients to motivate therapeutic modifications and increase patients' health.
Identifiants
pubmed: 34206415
pii: ijerph18136709
doi: 10.3390/ijerph18136709
pmc: PMC8293810
pii:
doi:
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Références
JAMA Dermatol. 2021 Apr 1;157(4):464-466
pubmed: 33625467
Br J Dermatol. 2017 Apr;176(4):993-1000
pubmed: 27564400
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):345-352
pubmed: 32531099
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31
pubmed: 30176066
Br J Dermatol. 2020 Jan;182(1):166-174
pubmed: 30919930
Dermatology. 2020;236(1):37-45
pubmed: 31434072
Acta Derm Venereol. 2017 Feb 8;97(2):208-213
pubmed: 27377144
PLoS One. 2017 Nov 7;12(11):e0187645
pubmed: 29112985
Niger Postgrad Med J. 2012 Jun;19(2):97-101
pubmed: 22728975
J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3
pubmed: 19293006
Am J Clin Dermatol. 2015 Feb;16(1):61-5
pubmed: 25432664
Dermatology. 2019;235(4):308-314
pubmed: 31121589
JAMA Dermatol. 2018 Apr 1;154(4):447-451
pubmed: 29466546
J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1633-1643
pubmed: 31037773
Acta Derm Venereol. 2021 Jan 5;101(1):adv00364
pubmed: 33320274
J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44
pubmed: 25640693
Br J Dermatol. 2020 Dec;183(6):e171-e177
pubmed: 29744872
Dermatology. 2020;236(5):393-412
pubmed: 32408306
Actas Dermosifiliogr (Engl Ed). 2019 Sep;110(7):554-560
pubmed: 31023484
J Affect Disord. 2012 Feb;136(3):716-23
pubmed: 22056230
Clin Exp Dermatol. 2017 Apr;42(3):261-265
pubmed: 28194809
Semin Cutan Med Surg. 2017 Jun;36(2):75-78
pubmed: 28538748
Skin Appendage Disord. 2017 Mar;3(1):20-27
pubmed: 28611997
Acta Derm Venereol. 2018 Jun 8;98(6):563-569
pubmed: 29507999
J Clin Med. 2019 Apr 18;8(4):
pubmed: 31003427
Life (Basel). 2021 Jan 08;11(1):
pubmed: 33429896
Cogn Neurodyn. 2017 Dec;11(6):565-571
pubmed: 29147148
Acta Derm Venereol. 2010 May;90(3):264-8
pubmed: 20526543
J Cutan Med Surg. 2018 Mar/Apr;22(2):166-174
pubmed: 29231053
J Clin Psychol Med Settings. 2020 Sep;27(3):527-540
pubmed: 31222671
Dermatology. 2016;232(6):687-691
pubmed: 28052274
Br J Dermatol. 2011 Jun;164(6):1292-8
pubmed: 21332464
J Am Acad Dermatol. 2012 Sep;67(3):422-8, 428.e1
pubmed: 22182915
Acta Derm Venereol. 2011 May;91(3):328-32
pubmed: 21394419
Eur J Pain. 2017 Jan;21(1):82-91
pubmed: 27301642
Br J Dermatol. 2021 Apr;184(4):681-687
pubmed: 32602129
Am J Clin Dermatol. 2017 Oct;18(5):687-695
pubmed: 28429245
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):50-61
pubmed: 32460374
Acta Derm Venereol. 2018 Aug 29;98(8):757-761
pubmed: 29756157
Clin J Pain. 2010 Jun;26(5):435-44
pubmed: 20473053
J Eur Acad Dermatol Venereol. 2013 Apr;27(4):473-8
pubmed: 22339940
Health Qual Life Outcomes. 2019 Jul 16;17(1):124
pubmed: 31311564
Acta Derm Venereol. 2018 Feb 7;98(2):191-194
pubmed: 28971209
Postgrad Med J. 2014 Apr;90(1062):216-21; quiz 220
pubmed: 24567417
Depress Anxiety. 2010 Feb;27(2):168-89
pubmed: 20143427
J Invest Dermatol. 2018 Jan;138(1):52-57
pubmed: 28942360
An Bras Dermatol. 2015 May-Jun;90(3):338-45
pubmed: 26131863
J Am Acad Dermatol. 2020 May;82(5):1232-1234
pubmed: 31730843
Dermatology. 2020;236(1):59-65
pubmed: 31466061
J Am Acad Dermatol. 2021 Jul;85(1):187-199
pubmed: 32950543
Br J Dermatol. 2021 Apr;184(4):772-774
pubmed: 33205398
PLoS One. 2016 Jun 21;11(6):e0157843
pubmed: 27327082
Br J Dermatol. 2017 May;176(5):1170-1178
pubmed: 28032340
JAMA Dermatol. 2019 Aug 1;155(8):939-945
pubmed: 31166590
Br J Dermatol. 2001 Apr;144(4):809-13
pubmed: 11298541
BMC Res Notes. 2012 Jan 20;5:52
pubmed: 22264277
JAMA Dermatol. 2017 Dec 1;153(12):1263-1269
pubmed: 29117300
Medicine (Baltimore). 2014 Dec;93(27):e187
pubmed: 25501066
Acta Derm Venereol. 2016 Feb;96(2):222-6
pubmed: 25940640
Dermatitis. 2016 Mar-Apr;27(2):50-8
pubmed: 26983091
Curr Pain Headache Rep. 2017 Nov 1;21(12):49
pubmed: 29094219
Eur J Dermatol. 2019 Jun 1;29(3):294-301
pubmed: 31145081
Arch Dermatol Res. 2020 Aug;312(6):427-436
pubmed: 31848682